Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphate binder effects on calciprotein particles in haemodialysis patients
ACTRN12617000881336Phase 4Recruiting
- Sponsor
- Royal Melbourne Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of calcium carbonate and sevelamer carbonate in chronic kidney disease (CKD) and hyperphosphatemia (3 arms), sponsored by Royal Melbourne Hospital. Primary endpoint: Levels of fetuin A-calciprotein particles in serum. Started Mar 2017; status: recruiting.
02
Drugs
calcium carbonatesevelamer carbonate
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on ACTRN12617000881336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000881336.